Dr. Jean-pierre Bizzari, M.d
Dr. Jean-Pierre Bizzari, M.D., served as a Vice President for Clinical Development Oncology at sanofi-aventis since November 2004 until 2008. From 1993 to 2004, Dr. Bizzari served as Vice President, Clinical Development Oncology at Rhone-Poulenc Rorer (Aventis). He joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France), after working as an Assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. Prior to that, he served as Vice President of Clinical Development Oncology for Sanofi-Synthelabo from 2002 to 2004. He has 33 years of industry experience with several major accomplishments including overseeing the approval of multiple leading oncology products. Dr. Bizzari served as Group Head of Clinical Oncology Development at Celgene Corporation since 2008. He served as Executive Vice-President at Celgene Corporation since 2008. Dr. Bizzari was responsible for Celgene's clinical development and operations-statistics teams across the U.S., Europe and Asia/Japan and has overseen the development and approval of a number of leading oncology products including Taxotere®, Eloxatin®, REVLIMID® (lenalidomide), VIDAZA® (azacitidine), ISTODAX® (romidepsin), Irinotecan® and ABRAXANEÂ® (nab-paclitaxel). In addition, he was Chairman of Celgene's hematology oncology development committee and a member of its management committee. He has been an Independent Director at Onxeo SA since April 6, 2016 and served as its Board Observer since January 2016. He has been a Director at Pieris Pharmaceuticals, Inc. since May 12, 2015 and Halozyme Therapeutics, Inc. since January 2015. He has been a Director of Celator Pharmaceuticals, Inc. since February 2015 and Nordic Nanovector ASA since May 19, 2016. He has been an Independent Director of Transgene SA since 2008. Since 2005, he has been a Member of the Scientific Advisory Board of the French National Cancer Research Institute. He has been Non-Executive Director of Oxford BioTherapeutics Ltd. since February 9, 2017. He has been a Member of Scientific Advisory Board at oncosynergy Inc., since May 10, 2016. He serves as a Member of the Scientific Advisory Board of Netrix Pharma. He has published more than 70 articles in peer review journals and more than 160 abstracts in scientific congresses. He is an Oncologist, having trained at La Pitie-Salpetriere hospital in Paris, followed by training at the Ontario Cancer Institute and McGill Cancer Center. Dr. Bizzari is graduate of the Nice medical school and a specialist in oncology. He received his Medical Degree from the University of Nice (France).
Clinical Oncology, Genetics